Autoantibodies to oxidized low density lipoprotein in relation with coronary artery disease [0.03%]
氧化低密度脂蛋白自身抗体与冠心病的关系研究
Yosdel Soto,Héctor Conde,Ronald Aroche et al.
Yosdel Soto et al.
The relationship between autoantibodies (autoAbs) to oxidized LDL (oxLDL) and coronary artery disease (CAD) remains controversial. IgM and IgG autoAbs to oxLDL and 1-palmitoyl-2 (5'-oxo-valeroyl)-sn-glycero-3-phosphorylcholine (POVPC), as w...
Immunizations of human lymphocytes in vitro with a T-dependent antigen towards human monoclonal antibody production [0.03%]
人单克隆抗体的产生免疫接种人类淋巴细胞体液免疫反应抗原依赖性T细胞
Ravi Maddaly,Priya Sivaramakrishnan,Solomon F D Paul
Ravi Maddaly
Human monoclonal antibodies have a plethora of applications, justifying the time and effort towards development of techniques for their efficient production. Attempts at establishing efficient reproducible techniques for activation of lymph...
Target therapy of cancer: implementation of monoclonal antibodies and nanobodies [0.03%]
癌症的靶向治疗：单克隆抗体和纳米体的应用实施
Jafar Majidi,Jaleh Barar,Behzad Baradaran et al.
Jafar Majidi et al.
In the past decades, the mainstay of systemic therapy for solid and haematological malignancies was chemotherapy; nevertheless this modality has the drawbacks such as drug resistance and eliciting sever cytotoxicity in the normal tissue. To...
Production of human antibodies to native cytokine receptors using the genetic immunization of KM mice [0.03%]
利用KM小鼠的遗传免疫产生人源细胞因子受体抗体
Akira Fujimoto,Shogo Takatsuka,Isao Ishida et al.
Akira Fujimoto et al.
We have established a protocol for generating antibodies to native G-protein coupled receptors using genetic immunization with a molecular adjuvant, E. coli Gro-EL. Here, we adapted this protocol for use in transchromosome KM mice, which be...
Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies [0.03%]
生物测定法在治疗性单克隆抗体定量及临床药代动力学研究中的应用
Carola W N Damen,Jan H M Schellens,Jos H Beijnen
Carola W N Damen
Monoclonal antibodies (mAbs) are an upcoming group of therapeutic compounds used to treat various types of diseases. Currently more than 100 mAbs are in clinical development. To establish the pharmacokinetic (PK) properties of mAbs many (pr...